Cosentyx
Prescription
Biologic (IL-17A Inhibitor)
Secukinumab Injection
Manufacturer: Novartis
Description
Cosentyx is Novartis' secukinumab — a fully human monoclonal antibody that selectively neutralises interleukin-17A (IL-17A), a key cytokine driving psoriatic inflammation. First-line biologic for moderate-to-severe plaque psoriasis in India with high PASI 90/100 response rates.
Active Compounds
No tracked compounds
Indications
- Moderate-to-severe plaque psoriasis
- Psoriatic arthritis
- Ankylosing spondylitis
Dosage
300mg subcutaneous injection at weeks 0, 1, 2, 3, 4, then 300mg every 4 weeks.
Formulations
Full Ingredient List
- Secukinumab
- Trehalose Dihydrate
- L-Histidine
- L-Histidine Hydrochloride Monohydrate
- L-Methionine
- Polysorbate 80
- Water for Injection
Side Effects
- Upper respiratory infections
- Injection site reactions
- Oral candidiasis
- Diarrhoea
- Neutropenia
Warnings
- Screen for tuberculosis before starting (mandatory in India)
- Avoid in active TB or serious infections
- Increased risk of mucocutaneous candidiasis
- May exacerbate inflammatory bowel disease
- Avoid live vaccines